HELMHOLTZ ZENTRUM MUNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEITND UMWELT (GMBH);TECHNISCHE UNIVERSITAT DRESDEN;HELMHOLTZ ZENTRUM MUNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH)
发明人:
ZIEGLER, ANETTE-G.,BONIFACIO, EZIO,WINKLER, CHRISTIANE,KRUMSIEK, JAN,THEIS, FABIAN,ACHENBACH, PETER
申请号：
CA3067713
公开号：
CA3067713A1
申请日:
2018.06.27
申请国别(地区):
CA
年份:
2019
代理人:
摘要：
The present invention relates to a method of determining whether a subject is at risk of developing type 1 diabetes by determining the genetic risk score (GRS) of a subject. The present invention also comprises a pharmaceutical composition comprising insulin and a pharmaceutical acceptable carrier for use in a method for preventing type 1 diabetes in a subject having a genetic risk score as determined by the method mentioned above. Further, it encompasses a kit for use in a method of determining whether a subject is at risk of developing type 1 diabetes by determining the genetic risk score of a subject and a type 1 diabetes antigen for use in a method of immunizing a subject against type 1 diabetes having a genetic risk score as determined by the method mentioned above.
